TriangleNCT01266967 · OUTCOME
Overall Survival of V600E Mutation-positive Participants
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Time from the first dose of study medication until death due to any cause (average of 35 weeks)
What was measured
Overall survival (OS) is defined as the time from the first dose of study medication until death due to any cause. OS was censored using the date of last known contact for those participants who were alive at the time of analysis.
Analysis population: V600E Population
Groups in this outcome
GSK2118436 150 mg: No Prior Local Therapy
Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
GSK2118436 150 mg: Prior Local Therapy
Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
| Group | Source count |
|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 74 |
| GSK2118436 150 mg: Prior Local Therapy | 65 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| GSK2118436 150 mg: No Prior Local Therapy | 6.8 | Not reported | 6.1 | 9.2 | Not reported |
| GSK2118436 150 mg: Prior Local Therapy | 7.6 | Not reported | 6.3 | 10.6 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 6.1
- upper Limit
- 9.2
- value
- 6.8
- group Id
- OG001
- lower Limit
- 6.3
- upper Limit
- 10.6
- value
- 7.6
- denoms
- counts
- group Id
- OG000
- value
- 74
- group Id
- OG001
- value
- 65
- units
- Participants
- description
- Overall survival (OS) is defined as the time from the first dose of study medication until death due to any cause. OS was censored using the date of last known contact for those participants who were alive at the time of analysis.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Participants who received no prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG000
- title
- GSK2118436 150 mg: No Prior Local Therapy
- description
- Participants who received prior local therapy for brain metastasis received GSK2118436 150 mg capsules either one hour before or 2 hours after a meal twice daily until evidence of disease progression, death, or unacceptable adverse events.
- id
- OG001
- title
- GSK2118436 150 mg: Prior Local Therapy
- param Type
- MEDIAN
- population Description
- V600E Population
- reporting Status
- POSTED
- time Frame
- Time from the first dose of study medication until death due to any cause (average of 35 weeks)
- title
- Overall Survival of V600E Mutation-positive Participants
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice